• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    New endocrine therapies for breast cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Howell, Anthony
    Downey, S
    Anderson, Elizabeth
    Affiliation
    CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, U.K.
    Issue Date
    1996-04
    
    Metadata
    Show full item record
    Abstract
    How do the new endocrine therapies stand up to the aims of modern endocrine therapy outlined in Table 1? We wish to see increased efficacy, decreased toxicity and improved general health in women taking a new agent. None of the new non-steroidal anti-oestrogens have shown unequivocal evidence of improved efficacy in the clinic to mirror their improved profiles over tamoxifen in preclinical studies. We know that toremifene is equivalent to tamoxifen, but we do not have any phase III data from the other four compounds in development. The specific steroidal antioestrogen, ICI 182,780, looks very promising, but is early in its developmental programme. The new aromatase inhibitors are likely to prove equal to tamoxifen or progestagens, but it is disappointing that improved oestrogen suppression has not led, to date, to improved efficacy. No comment can be made about adjuvant or preventative therapy for any of the new agents, although trials are planned for the new aromatase inhibitors in this clinical situation. Currently, the antiprogestins are disappointing and we will need to wait a considerable time for new agents in preclinical testing to reach the clinic. Many of the new agents are associated with decreased toxicity. It is likely that the NSAEs will be equitoxic with tamoxifen. The steroidal antioestrogen looks particularly non-toxic as do the new aromatase inhibitors, and thus we have an advance in terms of reduced toxicity. The effects of the new agents on the uterus, lipids and bone are in the early stages of testing. Raloxifene, ICI 182,780 and the new aromatase inhibitors are expected to have no proliferative effects on the endometrium, but only the new NSAEs are expected to have beneficial cardiovascular and skeletal effects. If the steroidal anti-oestrogens and new aromatase inhibitors become adjuvant therapies of choice, other agents to prevent osteoporosis and cardiovascular events may also have to be administered.
    Citation
    New endocrine therapies for breast cancer. 1996, 32A (4):576-88 Eur. J. Cancer
    Journal
    European Journal of Cancer
    URI
    http://hdl.handle.net/10541/95645
    DOI
    10.1016/0959-8049(96)00032-9
    PubMed ID
    8695256
    Type
    Article
    Language
    en
    ISSN
    0959-8049
    ae974a485f413a2113503eed53cd6c53
    10.1016/0959-8049(96)00032-9
    Scopus Count
    Collections
    All Christie Publications
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Update on endocrine therapy for breast cancer.
    • Authors: Buzdar AU, Hortobagyi G
    • Issue date: 1998 Mar
    • Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    • Authors: Robertson JF, Come SE, Jones SE, Beex L, Kaufmann M, Makris A, Nortier JW, Possinger K, Rutqvist LE
    • Issue date: 2005 Feb
    • Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    • Authors: Robertson JF
    • Issue date: 2004 Dec
    • Biological rationale for endocrine therapy in breast cancer.
    • Authors: Miller WR
    • Issue date: 2004 Mar
    • Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
    • Authors: Goss PE, Strasser K
    • Issue date: 2002
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.